An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rollefstad Silvia, Ikdahl Eirik, Wibetoe Grunde, Sexton Joe, Crowson Cynthia S, van Riel Piet, Kitas George D, Graham Ian, Dahlqvist Solbritt Rantapää, Karpouzas George, Myasoedova Elena, Gonzalez-Gay Miguel A, Sfikakis Petros P, Tektonidou Maria G, Lazarini Argyro, Vassilopoulos Dimitrios, Kuriya Bindee, Hitchon Carol A, Stoenoiu Maria Simona, Durez Patrick, Pascual-Ramos Virginia, Galarza-Delgado Dionicio Angel, Faggiano Pompilio, Misra Durga Prasanna, Borg Andrew, Mu Rong, Mirrakhimov Erkin M, Gheta Diane, Myasoedova Svetlana, Krougly Lev, Popkova Tatiana, Tuchyňová Alena, Tomcik Michal, Vrablik Michal, Lastuvka Jiri, Horák Pavel, Medková Helena, Semb Anne Grete
Аннотация
METHODS AND RESULTS: The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination.
CONCLUSION: We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.